Lab
Sunrise Medical Laboratories, INC.
Sunrise Medical Laboratories, INC. was paid $101.48M by Medicaid between Jan 2018 and Dec 2024, across 478 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 18% of everything it billed.
33Billing provider infoSUNRISE MEDICAL LABORATORIES, INC.
HICKSVILLE, NY 11801
HICKSVILLE, NY 11801
33aNPI1376587113assigned 06/15/2006
33bProvider typeClinical Medical Laboratory
28Total paid$101.48M
24GClaims10,153,997
24DCodes billed478
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New York
Rank by total paid#6 of 116
Median peer was paid$618K
This provider vs. median164×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,072,780 | $10.87M | |
| 2019 | 1,058,572 | $10.00M | |
| 2020 | 1,146,701 | $15.14M | |
| 2021 | 1,388,904 | $19.52M | |
| 2022 | 1,972,215 | $22.70M | |
| 2023 | 1,983,796 | $13.51M | |
| 2024incomplete | 1,531,029 | $9.74M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 18% | 281,657 | 258,045 | $18.31M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.0% | 296,520 | 288,764 | $5.07M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.7% | 295,192 | 287,483 | $4.80M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.0% | 301,122 | 296,507 | $4.02M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.9% | 189,979 | 174,986 | $3.97M |
| 80050 | General health panel | 3.4% | 228,729 | 225,736 | $3.43M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.4% | 158,000 | 151,581 | $2.42M |
| 80053 | Comprehensive metabolic panel | 2.1% | 426,164 | 413,566 | $2.18M |
| 80061 | Lipid panel | 2.1% | 472,187 | 464,818 | $2.17M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.0% | 135,195 | 134,262 | $2.08M |
| 86480 | 2.0% | 72,873 | 71,682 | $2.07M | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.0% | 47,207 | 44,976 | $2.04M |
466 more codes
| 86769 | 2.0% | 65,971 | $2.00M | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.9% | 182,304 | $1.93M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.9% | 109,025 | $1.92M |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.4% | 377,694 | $1.38M |
| 82607 | 1.3% | 191,632 | $1.33M | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 445,921 | $1.24M |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 241,135 | $1.23M |
| 86803 | <1% | 140,530 | $987K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 31,722 | $974K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 53,787 | $970K |
| 82746 | <1% | 131,131 | $896K | |
| 84439 | <1% | 201,047 | $842K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 17,959 | $821K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 214,366 | $819K |
| 87481 | <1% | 38,572 | $809K | |
| 86003 | <1% | 17,021 | $755K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 25,141 | $738K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 7,953 | $736K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 3,581 | $696K |
| 82728 | <1% | 99,626 | $598K | |
| 83013 | <1% | 17,095 | $580K | |
| 81001 | <1% | 344,698 | $575K | |
| 84403 | <1% | 40,041 | $546K | |
| 87340 | <1% | 93,824 | $543K | |
| 86706 | <1% | 95,631 | $534K | |
| 84153 | <1% | 66,224 | $527K | |
| 84481 | <1% | 73,314 | $521K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 5,443 | $512K |
| 86696 | <1% | 57,624 | $503K | |
| 87070 | <1% | 121,854 | $501K | |
| 87077 | <1% | 96,533 | $484K | |
| 80074 | <1% | 33,040 | $456K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 8,770 | $405K |
| 86762 | <1% | 46,914 | $362K | |
| 87186 | <1% | 80,633 | $360K | |
| 82670 | <1% | 23,918 | $355K | |
| 83001 | <1% | 34,565 | $354K | |
| 83655 | <1% | 51,315 | $349K | |
| 87511 | <1% | 23,813 | $339K | |
| 81514 | <1% | 4,846 | $339K | |
| 86235 | <1% | 17,058 | $321K | |
| 83970 | <1% | 15,778 | $317K | |
| 86592 | <1% | 150,204 | $316K | |
| 83002 | <1% | 31,262 | $315K | |
| 81513 | <1% | 12,368 | $313K | |
| 86765 | <1% | 44,207 | $310K | |
| 88141 | <1% | 27,015 | $306K | |
| 84702 | <1% | 42,079 | $301K | |
| 83550 | <1% | 93,807 | $295K | |
| 84146 | <1% | 27,663 | $290K | |
| 86708 | <1% | 44,510 | $283K | |
| 86695 | <1% | 53,636 | $282K | |
| 86787 | <1% | 42,011 | $282K | |
| 83540 | <1% | 108,059 | $280K | |
| 86704 | <1% | 46,153 | $271K | |
| 87480 | <1% | 25,245 | $261K | |
| 87510 | <1% | 24,122 | $252K | |
| 86735 | <1% | 39,274 | $239K | |
| 87536 | <1% | 4,050 | $238K | |
| 86780 | <1% | 36,438 | $229K | |
| 87522 | Neg quan hep c or qual rna | <1% | 8,910 | $222K |
| 86694 | <1% | 34,326 | $209K | |
| 86038 | <1% | 42,263 | $201K | |
| 87634 | <1% | 9,639 | $200K | |
| 86376 | <1% | 26,492 | $199K | |
| 87081 | <1% | 55,535 | $189K | |
| 80081 | <1% | 5,805 | $189K | |
| 82570 | <1% | 74,098 | $180K | |
| 82043 | <1% | 69,343 | $180K | |
| 87660 | <1% | 17,299 | $178K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,544 | $178K |
| 84550 | <1% | 74,652 | $173K | |
| 84144 | <1% | 15,449 | $170K | |
| 85027 | <1% | 56,524 | $167K | |
| 83021 | <1% | 17,103 | $166K | |
| 88112 | <1% | 5,880 | $166K | |
| 84270 | <1% | 22,010 | $163K | |
| 87529 | <1% | 5,692 | $161K | |
| 82627 | <1% | 13,036 | $152K | |
| 86800 | <1% | 19,596 | $152K | |
| 84480 | <1% | 28,556 | $150K | |
| 86618 | <1% | 14,969 | $150K | |
| 81511 | <1% | 2,672 | $149K | |
| 84154 | <1% | 15,344 | $142K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 39,605 | $137K |
| 82784 | <1% | 19,758 | $135K | |
| 83735 | <1% | 47,279 | $135K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 874 | $126K |
| 86140 | <1% | 54,650 | $125K | |
| 82652 | <1% | 13,580 | $122K | |
| 87517 | <1% | 9,263 | $122K | |
| 86364 | <1% | 8,601 | $116K | |
| 82248 | <1% | 47,351 | $116K | |
| 88142 | <1% | 10,132 | $116K | |
| 82785 | <1% | 14,173 | $115K | |
| 86147 | <1% | 5,365 | $111K | |
| 86617 | <1% | 9,065 | $110K | |
| 84436 | <1% | 39,369 | $110K | |
| 87563 | <1% | 8,099 | $108K | |
| 88342 | <1% | 2,697 | $107K | |
| 83521 | <1% | 2,988 | $100K | |
| 86709 | <1% | 17,796 | $99K | |
| 86160 | <1% | 12,313 | $99K | |
| 83525 | <1% | 16,472 | $97K | |
| 86665 | <1% | 5,411 | $96K | |
| 86360 | <1% | 3,136 | $94K | |
| 87467 | <1% | 14,028 | $89K | |
| 87350 | <1% | 15,702 | $89K | |
| 85652 | <1% | 73,101 | $88K | |
| 86707 | <1% | 15,528 | $88K | |
| 84402 | <1% | 6,315 | $87K | |
| 83498 | <1% | 5,771 | $86K | |
| 82105 | <1% | 14,113 | $83K | |
| 87147 | <1% | 37,905 | $77K | |
| 86430 | <1% | 25,258 | $76K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 281,171 | $72K |
| 86225 | <1% | 14,531 | $72K | |
| 83516 | <1% | 10,668 | $71K | |
| 80076 | <1% | 18,434 | $71K | |
| 86255 | <1% | 12,032 | $69K | |
| 82626 | <1% | 4,937 | $67K | |
| 86200 | <1% | 16,567 | $65K | |
| 82533 | <1% | 7,745 | $64K | |
| 86334 | <1% | 6,516 | $63K | |
| 82550 | <1% | 22,422 | $63K | |
| 83520 | <1% | 11,046 | $61K | |
| 83690 | <1% | 17,739 | $57K | |
| 86008 | <1% | 2,159 | $57K | |
| 83090 | <1% | 6,018 | $57K | |
| 86705 | <1% | 10,338 | $56K | |
| 83880 | <1% | 4,170 | $56K | |
| 84100 | <1% | 23,639 | $55K | |
| 86258 | <1% | 3,893 | $54K | |
| 86141 | <1% | 9,184 | $54K | |
| 86747 | <1% | 4,662 | $53K | |
| 88361 | <1% | 799 | $52K | |
| 86015 | <1% | 3,135 | $51K | |
| 85610 | <1% | 28,667 | $51K | |
| 81329 | <1% | 1,676 | $50K | |
| 82274 | <1% | 9,374 | $50K | |
| 87653 | <1% | 3,232 | $50K | |
| 82977 | <1% | 17,632 | $49K | |
| 84445 | <1% | 3,139 | $48K | |
| 84425 | <1% | 5,093 | $48K | |
| 84165 | <1% | 10,623 | $48K | |
| 86317 | <1% | 4,850 | $48K | |
| 84479 | <1% | 20,225 | $47K | |
| 82378 | <1% | 5,545 | $47K | |
| 87631 | <1% | 1,117 | $46K | |
| 82465 | <1% | 21,935 | $46K | |
| 82150 | <1% | 14,839 | $45K | |
| 84681 | <1% | 4,150 | $43K | |
| 85730 | <1% | 19,453 | $42K | |
| 87255 | <1% | 2,997 | $41K | |
| 86757 | <1% | 2,418 | $41K | |
| 86146 | <1% | 2,014 | $38K | |
| 86357 | <1% | 2,200 | $37K | |
| 82951 | <1% | 6,787 | $37K | |
| 82157 | <1% | 2,411 | $37K | |
| 87338 | <1% | 6,298 | $36K | |
| 86850 | <1% | 9,947 | $36K | |
| 86359 | <1% | 2,203 | $36K | |
| 82950 | <1% | 14,392 | $34K | |
| 82024 | <1% | 1,795 | $33K | |
| 87045 | <1% | 4,839 | $33K | |
| 83615 | <1% | 12,409 | $33K | |
| 81243 | <1% | 2,771 | $33K | |
| 82677 | <1% | 2,511 | $32K | |
| 84163 | <1% | 3,978 | $32K | |
| 87902 | <1% | 182 | $31K | |
| 87106 | <1% | 5,392 | $30K | |
| 86664 | <1% | 3,581 | $29K | |
| 86666 | <1% | 3,175 | $29K | |
| 87177 | <1% | 5,540 | $29K | |
| 81596 | <1% | 1,289 | $28K | |
| 84460 | <1% | 10,592 | $28K | |
| 82671 | <1% | 2,974 | $27K | |
| 86812 | <1% | 2,998 | $27K | |
| 86901 | <1% | 15,507 | $27K | |
| 81401 | <1% | 665 | $27K | |
| 81507 | <1% | 230 | $27K | |
| 84156 | <1% | 15,521 | $26K | |
| 83921 | <1% | 2,520 | $26K | |
| 86900 | <1% | 15,721 | $25K | |
| 88173 | <1% | 536 | $25K | |
| 80069 | <1% | 3,848 | $25K | |
| 86663 | <1% | 3,437 | $24K | |
| 83721 | <1% | 11,565 | $24K | |
| 87329 | <1% | 3,716 | $23K | |
| 86777 | <1% | 2,902 | $23K | |
| 86304 | <1% | 2,844 | $23K | |
| 87102 | <1% | 4,553 | $22K | |
| 84207 | <1% | 1,638 | $22K | |
| 86231 | <1% | 3,212 | $22K | |
| 84305 | <1% | 2,041 | $22K | |
| 80349 | <1% | 6,718 | $21K | |
| 86039 | <1% | 4,783 | $21K | |
| 84466 | <1% | 3,836 | $21K | |
| 85045 | <1% | 11,217 | $20K | |
| 86021 | <1% | 3,909 | $20K | |
| 81376 | <1% | 521 | $20K | |
| 86300 | <1% | 2,448 | $20K | |
| 83010 | <1% | 3,428 | $20K | |
| 82672 | <1% | 1,753 | $20K | |
| 87799 | <1% | 457 | $20K | |
| 86738 | <1% | 1,699 | $20K | |
| 80348 | <1% | 3,283 | $19K | |
| 80055 | <1% | 813 | $19K | |
| 84590 | <1% | 2,948 | $19K | |
| 87581 | <1% | 1,174 | $19K | |
| 87486 | <1% | 1,163 | $19K | |
| 84703 | <1% | 6,501 | $19K | |
| 87046 | <1% | 4,233 | $19K | |
| 86355 | <1% | 1,251 | $19K | |
| 82172 | <1% | 1,786 | $18K | |
| 82985 | <1% | 2,609 | $17K | |
| 87209 | <1% | 2,757 | $17K | |
| 86671 | <1% | 1,785 | $17K | |
| 86778 | <1% | 2,250 | $17K | |
| 84432 | <1% | 3,184 | $17K | |
| 88120 | <1% | 74 | $17K | |
| 86431 | <1% | 7,082 | $16K | |
| 84075 | <1% | 6,613 | $16K | |
| 80365 | <1% | 5,939 | $16K | |
| 82088 | <1% | 957 | $16K | |
| 86336 | <1% | 2,184 | $16K | |
| 85379 | <1% | 3,015 | $15K | |
| 86256 | <1% | 1,944 | $15K | |
| 82668 | <1% | 2,144 | $15K | |
| 86710 | <1% | 1,029 | $15K | |
| 84478 | <1% | 7,375 | $15K | |
| 82397 | <1% | 3,235 | $14K | |
| 84630 | <1% | 2,665 | $14K | |
| 80164 | <1% | 2,532 | $14K | |
| 83883 | <1% | 1,792 | $14K | |
| 86644 | <1% | 1,791 | $14K | |
| 82653 | <1% | 641 | $13K | |
| 82164 | <1% | 2,755 | $13K | |
| 81002 | <1% | 9,004 | $13K | |
| 87075 | <1% | 2,955 | $13K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 223 | $13K |
| 86036 | <1% | 890 | $12K | |
| 86645 | <1% | 1,582 | $12K | |
| 82330 | <1% | 2,190 | $12K | |
| 84181 | <1% | 909 | $12K | |
| 82390 | <1% | 2,415 | $12K | |
| 82947 | <1% | 6,104 | $12K | |
| 84450 | <1% | 9,806 | $12K | |
| 86356 | <1% | 1,492 | $12K | |
| 82525 | <1% | 1,713 | $12K | |
| 87625 | <1% | 1,250 | $12K | |
| 83993 | <1% | 1,565 | $12K | |
| 82103 | <1% | 1,776 | $12K | |
| 87324 | <1% | 2,069 | $12K | |
| 88184 | <1% | 733 | $12K | |
| 87469 | <1% | 752 | $11K | |
| 87449 | <1% | 2,533 | $11K | |
| 87341 | <1% | 2,015 | $11K | |
| 88189 | <1% | 530 | $10K | |
| 85613 | <1% | 2,324 | $10K | |
| 84446 | <1% | 1,339 | $10K | |
| 83789 | <1% | 1,141 | $9K | |
| 86611 | <1% | 701 | $9K | |
| 87468 | <1% | 704 | $9K | |
| 87507 | <1% | 138 | $9K | |
| 86677 | <1% | 679 | $9K | |
| 82565 | <1% | 4,377 | $9K | |
| 87272 | <1% | 1,350 | $9K | |
| 82166 | <1% | 657 | $9K | |
| 86593 | <1% | 3,910 | $9K | |
| 87328 | <1% | 1,517 | $9K | |
| 87109 | <1% | 1,261 | $9K | |
| 84166 | <1% | 1,079 | $8K | |
| 86631 | <1% | 796 | $8K | |
| 84080 | <1% | 1,333 | $8K | |
| 81003 | <1% | 8,486 | $8K | |
| 87185 | <1% | 3,478 | $8K | |
| 87484 | <1% | 622 | $8K | |
| 88262 | <1% | 141 | $8K | |
| 84155 | <1% | 8,903 | $8K | |
| 82787 | <1% | 663 | $8K | |
| 84255 | <1% | 773 | $8K | |
| 86301 | <1% | 1,276 | $8K | |
| 82955 | <1% | 1,505 | $7K | |
| 82232 | <1% | 1,242 | $7K | |
| 87101 | <1% | 1,743 | $7K | |
| 83695 | <1% | 1,937 | $7K | |
| 82642 | <1% | 755 | $7K | |
| 80346 | <1% | 2,555 | $7K | |
| 82310 | <1% | 3,326 | $7K | |
| 81256 | <1% | 455 | $7K | |
| 84520 | <1% | 4,040 | $7K | |
| 86341 | <1% | 798 | $6K | |
| 87912 | <1% | 67 | $6K | |
| 82085 | <1% | 1,920 | $6K | |
| 84484 | <1% | 1,408 | $6K | |
| 81241 | <1% | 330 | $6K | |
| 80324 | <1% | 2,027 | $6K | |
| 84482 | <1% | 1,289 | $6K | |
| 80178 | <1% | 1,791 | $6K | |
| 80177 | <1% | 1,144 | $6K | |
| 86753 | <1% | 911 | $6K | |
| 86335 | <1% | 490 | $6K | |
| 82308 | <1% | 468 | $6K | |
| 86632 | <1% | 794 | $6K | |
| 87478 | <1% | 415 | $6K | |
| 86063 | <1% | 2,159 | $6K | |
| 84378 | <1% | 915 | $6K | |
| 87471 | <1% | 470 | $6K | |
| 86308 | <1% | 2,072 | $6K | |
| 87512 | <1% | 355 | $6K | |
| 85660 | <1% | 2,458 | $6K | |
| 80159 | <1% | 771 | $6K | |
| 83718 | <1% | 3,037 | $5K | |
| 87623 | <1% | 1,151 | $5K | |
| 88185 | <1% | 132 | $5K | |
| 80361 | <1% | 1,823 | $5K | |
| 83835 | <1% | 627 | $5K | |
| 80359 | <1% | 2,310 | $5K | |
| 82180 | <1% | 976 | $5K | |
| 81291 | <1% | 567 | $5K | |
| 88280 | <1% | 434 | $5K | |
| 82679 | <1% | 259 | $4K | |
| 83519 | <1% | 803 | $4K | |
| 82552 | <1% | 719 | $4K | |
| 85240 | <1% | 639 | $4K | |
| 84244 | <1% | 782 | $4K | |
| 86702 | <1% | 961 | $4K | |
| 82247 | <1% | 6,209 | $4K | |
| 86692 | <1% | 400 | $4K | |
| 82610 | <1% | 705 | $4K | |
| 86885 | <1% | 1,799 | $4K | |
| 87040 | <1% | 462 | $4K | |
| 83630 | <1% | 536 | $4K | |
| 85384 | <1% | 808 | $4K | |
| 82270 | <1% | 1,828 | $3K | |
| 85007 | <1% | 2,576 | $3K | |
| 82107 | <1% | 140 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 823 | $3K |
| 87205 | <1% | 1,704 | $3K | |
| 84134 | <1% | 511 | $3K | |
| 81015 | <1% | 2,244 | $3K | |
| 85246 | <1% | 333 | $3K | |
| 82040 | <1% | 5,553 | $3K | |
| 86701 | <1% | 982 | $3K | |
| 84442 | <1% | 446 | $3K | |
| 87641 | <1% | 168 | $3K | |
| 86340 | <1% | 406 | $3K | |
| 81240 | <1% | 156 | $3K | |
| 80362 | <1% | 830 | $3K | |
| 82952 | <1% | 948 | $2K | |
| 86148 | <1% | 229 | $2K | |
| 86622 | <1% | 527 | $2K | |
| 83704 | <1% | 365 | $2K | |
| 86886 | <1% | 816 | $2K | |
| 80320 | <1% | 383 | $2K | |
| 80353 | <1% | 1,085 | $2K | |
| 83014 | <1% | 775 | $2K | |
| 86337 | <1% | 294 | $2K | |
| 87593 | <1% | 49 | $2K | |
| 84132 | <1% | 1,066 | $2K | |
| 86331 | <1% | 293 | $2K | |
| 82239 | <1% | 292 | $2K | |
| 88304 | <1% | 83 | $2K | |
| 82747 | <1% | 191 | $2K | |
| 84300 | <1% | 872 | $2K | |
| 80051 | <1% | 618 | $2K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 417 | $2K |
| 83003 | <1% | 197 | $2K | |
| 82530 | <1% | 214 | $2K | |
| 85245 | <1% | 211 | $2K | |
| 85306 | <1% | 192 | $1K | |
| 80175 | <1% | 225 | $1K | |
| 81050 | <1% | 1,229 | $1K | |
| 88341 | <1% | 54 | $1K | |
| 84597 | <1% | 183 | $1K | |
| 80197 | <1% | 243 | $1K | |
| 83020 | <1% | 189 | $1K | |
| 85014 | <1% | 1,270 | $1K | |
| 86361 | <1% | 74 | $1K | |
| 86215 | <1% | 181 | $1K | |
| 82542 | <1% | 143 | $1K | |
| 85018 | <1% | 1,222 | $1K | |
| 87476 | <1% | 50 | $1K | |
| 80358 | <1% | 585 | $1K | |
| 87273 | <1% | 137 | $1K | |
| 86162 | <1% | 94 | $1K | |
| 82608 | <1% | 119 | $1K | |
| 82710 | <1% | 86 | $999.08 | |
| 86658 | <1% | 94 | $989.45 | |
| 82495 | <1% | 70 | $980.94 | |
| 83698 | <1% | 53 | $979.82 | |
| 82272 | <1% | 570 | $861.78 | |
| 84238 | <1% | 165 | $848.39 | |
| 85303 | <1% | 118 | $844.82 | |
| 85300 | <1% | 148 | $819.33 | |
| 87493 | <1% | 64 | $803.51 | |
| 81257 | <1% | 330 | $776.77 | |
| 82140 | <1% | 106 | $770.78 | |
| 87274 | <1% | 90 | $711.81 | |
| 81361 | <1% | 25 | $699.28 | |
| 87015 | <1% | 280 | $654.09 | |
| 82595 | <1% | 235 | $618.99 | |
| 85247 | <1% | 86 | $568.94 | |
| 82731 | <1% | 13 | $560.68 | |
| 88235 | <1% | 12 | $558.55 | |
| 82365 | <1% | 82 | $533.56 | |
| 85049 | <1% | 730 | $487.50 | |
| 82384 | <1% | 55 | $485.86 | |
| 0107U | <1% | 215 | $475.24 | |
| 86870 | <1% | 41 | $422.92 | |
| 83527 | <1% | 60 | $422.12 | |
| 82374 | <1% | 358 | $397.45 | |
| 84295 | <1% | 513 | $386.08 | |
| 84704 | <1% | 60 | $382.31 | |
| 88108 | <1% | 85 | $371.44 | |
| 80414 | <1% | 12 | $369.23 | |
| 86880 | <1% | 187 | $346.53 | |
| 87280 | <1% | 54 | $339.60 | |
| 87535 | <1% | 43 | $339.50 | |
| 84588 | <1% | 13 | $334.65 | |
| 84586 | <1% | 13 | $296.91 | |
| 83825 | <1% | 24 | $295.44 | |
| 87168 | <1% | 201 | $286.95 | |
| 81270 | <1% | 25 | $274.98 | |
| 89060 | <1% | 83 | $273.62 | |
| 87400 | <1% | 28 | $272.67 | |
| 87252 | <1% | 13 | $233.28 | |
| 85305 | <1% | 26 | $229.74 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 227 | $229.27 |
| 87497 | <1% | 21 | $227.68 | |
| 80306 | <1% | 31 | $220.22 | |
| 82435 | <1% | 424 | $215.03 | |
| 80325 | <1% | 265 | $206.28 | |
| 87116 | <1% | 36 | $200.88 | |
| 80373 | <1% | 13 | $171.12 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 66 | $143.31 |
| 85302 | <1% | 12 | $141.63 | |
| 80354 | <1% | 317 | $140.10 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 89 | $139.05 |
| 82575 | <1% | 28 | $129.93 | |
| 82104 | <1% | 13 | $123.76 | |
| 85046 | <1% | 44 | $117.78 | |
| 80183 | <1% | 12 | $103.98 | |
| 85307 | <1% | 12 | $98.18 | |
| 82681 | <1% | 13 | $97.79 | |
| 83935 | <1% | 40 | $74.98 | |
| 87210 | <1% | 26 | $64.64 | |
| 86682 | <1% | 12 | $62.49 | |
| 84133 | <1% | 31 | $54.68 | |
| 83930 | <1% | 15 | $54.21 | |
| 82436 | <1% | 27 | $49.80 | |
| 85597 | <1% | 14 | $46.75 | |
| 85041 | <1% | 29 | $45.36 | |
| 85598 | <1% | 13 | $44.95 | |
| 87206 | <1% | 17 | $41.03 | |
| 87140 | <1% | 14 | $40.10 | |
| 82340 | <1% | 12 | $39.82 | |
| 89320 | <1% | 291 | $38.78 | |
| 89051 | <1% | 13 | $38.39 | |
| 85670 | <1% | 12 | $25.73 | |
| 89050 | <1% | 15 | $24.32 | |
| 87181 | <1% | 13 | $20.14 | |
| 80047 | 0% | 27 | $0.00 | |
| 99080 | 0% | 362 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGREENBERG, ALAN (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| East Side Clinical Laboratory, INC. | East Providence, RI | $48.64M |
| Innovation Optics | Roselle Park, NJ | $269K |
| Innovative Eyewear | Short Hills, NJ | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.